Skip to main content

Displaying 71 - 80 of 282

Testing Whether A Novel MRI Imaging Approach Will Find Aggressive Disease before Surgery, which May Help Physicians Decide the Best Treatment Plan for Patients with Newly Diagnosed Prostate Cancer

Prostate

This phase II trial studies how well multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning in patients with prostate cancer. Multiparametric MRI may be useful for evaluating the type of cancer in finding aggressive disease.
Prostate
II
Planz, Virginia
NCT03697148
ECOGUROEA8171

Near Infrared Autofluorescence Imaging for Identifying Parathyroid Glands during Parathyroidectomy

Endocrine

This trial investigates how well near infrared autofluorescence imaging works in identifying parathyroid glands during surgery to remove one or more parathyroid glands (parathyroidectomy). The parathyroid gland is an important organ in the neck that regulates calcium levels in the body. Thus, it is essential for a surgeon to correctly identify this organ when performing parathyroid surgeries. By assisting the surgeon in correctly identifying a diseased parathyroid gland, the 'PTeye' near infrared autofluorescence imaging device may improve the quality of the operation performed on the patient. This trial may determine if the PTeye truly benefits a patient undergoing surgery for parathyroid disease or not.
Endocrine
N/A
Solorzano, Carmen
NCT04299425
VICCHN2063

Near Infrared Autofluorescence via PTeye for the Detection of Parathyroid Glands during Total Thyroid Surgery

Thyroid

This trial studies how well infrared autofluorescence via PTeye works in detecting parathyroid glands during total thyroid surgery. Located closely to the thyroid gland are the parathyroid glands, which are important organs that regulate calcium levels in the body. Thus, it is essential for a surgeon to correctly identify this structure when performing a thyroid surgery. PTeye may help surgeon to identify and preserve healthy parathyroid glands during surgery. By assisting the surgeon in correctly identifying parathyroid glands, this device may improve the quality of the operation performed on the patient.
Thyroid
N/A
Solorzano, Carmen
NCT04281875
VICCHN2017

Wren Melanoma Study

Melanoma

Melanoma
N/A
Kauffmann, Rondi
NCT03267381
VICCMEL1783

The COVID-19 and Cancer Consortium (CCC19) Registry

Miscellaneous

Miscellaneous
N/A
Warner, Jeremy
NCT04354701
VICCMD2032

Molecular Predictors of Lung Cancer Behavior. (SPORE)

Multiple Cancer Types

Lung, Non Small Cell, Small Cell
N/A
Maldonado, Fabien
NCT00898313
VICCTHO0398

A Study of Combination Chemotherapy for Patients with Newly Diagnosed DAWT and Relapsed FHWT

Multiple Cancer Types

This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE / Cyclo / Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out what effects, good and / or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT) and regimen ICE / Cyclo / Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial WT).
Pediatrics, Wilms / Other Kidney (Pediatrics)
II
Benedetti, Daniel
NCT04322318
COGAREN1921

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients with Chronic Phase Chronic Myeloid Leukemia

Multiple Cancer Types

This phase II trial studies how stopping tyrosine kinase inhibitors will affect treatment-free remission in patients with chronic myeloid leukemia in chronic phase. When the level of disease is very low, it's called molecular remission. TKIs are a type of medication that help keep this level low. However, after being in molecular remission for a specific amount of time, it may not be necessary to take tyrosine kinase inhibitors. It is not yet known whether stopping tyrosine kinase inhibitors will help patients with chronic myeloid leukemia in chronic phase continue or re-achieve molecular remission.
Leukemia, Pediatric Leukemia, Pediatrics
II
Zarnegar-Lumley, Sara
NCT03817398
COGAAML18P1

Accelerated or Standard BEP Chemotherapy in Treating Patients with Intermediate or Poor-Risk Metastatic Germ Cell Tumors

Germ Cell (Pediatrics)

This phase III trial compares the effect of an accelerated schedule of bleomycin sulfate, etoposide phosphate, and cisplatin (BEP) chemotherapy to the standard schedule of BEP chemotherapy for the treatment of patients with intermediate or poor-risk germ cell tumors that have spread to other places in the body (metastatic). Drugs used in chemotherapy, such as bleomycin sulfate, etoposide phosphate, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BEP chemotherapy on a faster, or accelerated schedule may work better with fewer side effects in treating patients with intermediate or poor-risk metastatic germ cell tumors compared to the standard schedule.
Germ Cell (Pediatrics)
III
Borinstein, Scott
NCT02582697
COGAGCT1532

Nivolumab in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Multiple Cancer Types

This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nivolumab with chemo-immunotherapy may help treat patients with PMBCL.
Lymphoma, Pediatric Lymphoma, Pediatrics
III
Smith, Christine
NCT04759586
COGANHL1931